Literature DB >> 3707646

Ibopamine, an orally active dopamine-like drug: metabolism and pharmacokinetics in dogs.

F Pocchiari, R Pataccini, P Castelnovo, A Longo, M Paro, C Casagrande.   

Abstract

Ibopamine (SB-7505), the 3,4-diisobutyryl ester of N-methyldopamine (epinine), exerts, on oral administration, cardiovascular effects similar to those of intravenously infused dopamine. Plasma levels and urinary excretion of metabolites were investigated in dogs after oral administration of 4 mg/kg of ibopamine hydrochloride. Epinine, which was readily formed from ibopamine by esterases hydrolysis, was present in plasma in free and sulphate-conjugated form. The urinary metabolites after 6 h from the administration amounted to 62% of the dose, as a sum of 37% of epinine 3-O-sulphate, and 15 and 10% of 4-hydroxy-3-methoxyphenylacetic acid and 3,4-dihydroxyphenylacetic acid, respectively, both in free and conjugated form. When the main metabolite, epinine 3-O-sulphate, was administered intravenously it appeared to be excreted in urine without being deconjugated to any detectable extent, while it appeared to be partially deconjugated on oral administration.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3707646

Source DB:  PubMed          Journal:  Arzneimittelforschung        ISSN: 0004-4172


  3 in total

Review 1.  Pharmacokinetics of newer drugs in patients with renal impairment (Part II).

Authors:  E Singlas; J P Fillastre
Journal:  Clin Pharmacokinet       Date:  1991-05       Impact factor: 6.447

2.  Ibopamine-induced reduction of serum prolactin level and milk secretion in puerperal women.

Authors:  C Nappi; G Colace; P Affinito; M Taglialatela; G F Di Renzo; U Montemagno; L Annunziato
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Differential cardiovascular and neuroendocrine effects of epinine and dopamine in conscious pigs before and after adrenoceptor blockade.

Authors:  L J van Woerkens; F Boomsma; A J Man in 't Veld; M M Bevers; P D Verdouw
Journal:  Br J Pharmacol       Date:  1992-10       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.